deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT04778397

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (ENHANCE-2)

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia

Sponsor: Gilead Sciences

Conditions Acute Myeloid Leukemia
Interventions Azacitidine Cytarabine Daunorubicin Idarubicin Magrolimab Steroidal Eye Drops Venetoclax
Updated 30 times since 2021 Last updated: Feb 4, 2025 Started: Jul 1, 2021 Primary completion: Mar 25, 2024 Completion: Mar 25, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study discontinued due to futility.

Other terminated trials from Gilead Sciences

See all terminations from Gilead Sciences

Other Acute Myeloid Leukemia trials with similar outcome

Browse all Acute Myeloid Leukemia trials

This PHASE3 trial investigates Acute Myeloid Leukemia and is currently terminated or withdrawn. Gilead Sciences leads this study, which shows 30 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~May 2024 · 4 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Mar 2025 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Sep 2024 — Mar 2025 [monthly]

    Terminated PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  5. May 2024 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

▶ Show 25 earlier versions

  1. Jan 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  5. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  6. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  7. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  8. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  9. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  10. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  11. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  12. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  13. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  14. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  15. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  16. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  17. Mar 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  18. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  19. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  20. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  21. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  22. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  23. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

  24. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE3

  25. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aalborg, Denmark , Adelaide, Australia , Alicante, Spain , Amagasaki, Japan , Ancona, Italy , Angers, France , Atlanta, United States , Baltimore, United States , Barcelona, Spain and 128 more locations